Program
cofrogliptin
Its studies are mostly in Diabetes Mellitus, Type 2, led by Haisco Pharmaceutical Group.
Furthest: no phase, since Aug 7, 20251 company-led study, 1 open or runningNext primary completion: Jun 30, 2027
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Haisco Pharmaceutical Group | 11 open or running | no phasesince Aug 7, 2025 | Aug 7, 2025 | Jun 30, 2027NCT07122102 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 7, 2025First study: no phase study in Diabetes Mellitus, Type 2First studyNCT07122102 · 200 planned · China
Ahead
- Jun 30, 2027Primary completion: no phase study in Diabetes Mellitus, Type 2NCT07122102
TargetBeta
DPP4 →read by rule
“Cofrogliptin is a novel, ultra-long-acting DPP-4 inhibitor.”study text, by rule · the study
Other programs on DPP4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sitagliptinrule | Merck | phase 4 | 123 |
| Linagliptinrule | Boehringer Ingelheim | phase 4 | 96 |
| gemigliptinrule | LG Chem | phase 4 | 30 |
| anagliptinrule | JW Pharmaceutical | phase 4 | 6 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07122102Diabetes Mellitus, Type 2 · China | – | Not yet recruiting | Jun 30, 2027 | 200 |
How it is read
Names in the registry
- “Cofrogliptin”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.